

UNC Lineberger Cancer Network  
NORTH CAROLINA  
COMMUNITY COLLEGE @UNCLCN  
ONCOLOGY WEBINARS

October 25, 2022

Welcome to the  
UNC Lineberger Cancer Network's  
live webinar

Contact UNCLCN  
Phone: (919) 445-1000  
Email: unclcn@unc.edu  
Website: unclcn.org

Sound Check 3:55 PM Start Time 4:00 PM

Poll Everywhere is used for Q&A. More information at: [polllev.com/unclcn](https://polllev.com/unclcn)

For any technical difficulties: (919) 445-1000 [unclcn@unc.edu](mailto:unclcn@unc.edu)

While waiting, check out our upcoming webinars: [learn.unclcn.org/live](https://learn.unclcn.org/live)

The University of North Carolina is an equal opportunity institution. All programs and services are provided without regard to race, sex, age, religion, or national origin.

1

---

---

---

---

---

---

---

---

---

---

POLL EVERYWHERE

Join by Web

- Go to PollEv.com
- Enter UNCLCN
- Respond to activity

2

---

---

---

---

---

---

---

---

---

---

CONTINUING EDUCATION CREDITS

FREE CE Credits with Live Webinars

<p><b>PATIENT CENTERED CARE</b> 2nd Wednesday 12 pm - 1 pm NCPD/CNE ACPE ASRT CTR</p>	<p><b>ADVANCED PRACTICE PROVIDER</b> 3rd Wednesday 4 pm - 5 pm NCPD/CNE</p>
<p><b>RESEARCH TO PRACTICE</b> 4th Wednesday 12 pm - 1 pm NCPD/CNE CME ASRT CTR</p>	<p><b>SOUTHEASTERN AMERICAN INDIAN CANCER HEALTH EQUITY PARTNERSHIP</b> 1st Wednesday - February, May and November 12 pm - 1 pm (Nov 30 for 2022) NCPD/CNE CME</p>

FREE CE Credits with Self-Paced, Online Courses  
Courses are Available any Day and Time that is Convenient for You  
[learn.unclcn.org](https://learn.unclcn.org)

3

---

---

---

---

---

---

---

---

---

---



Respond at [polllev.com/uncnclcn](https://polllev.com/uncnclcn)  
Text UNCLCN to 22333 once to join, then A or B

UNC Lineberger Cancer Network

**Breast cancer can occur in women and rarely in men.**

True **A**

False **B**

Powered by **Poll Everywhere**

7

---

---

---

---


---

---

---

---

**OUR PRESENTER**



Amy DePue, RN, MSN, OCN, CCRN

Amy DePue has been an oncology nurse for the past 18+ years. She has been embedded with the breast oncology division at UNC Healthcare since May of 2011 as a nurse navigator. She holds certifications in general oncology as well as breast cancer care by the Oncology Nursing Society. She resides in Chapel Hill with the youngest of her five children and her three dogs, Max, Levi, and Arlo.

8

---

---

---

---

---

---

---

---

When poll is active, respond at [polllev.com/uncnclcn](https://polllev.com/uncnclcn)  
Text UNCLCN to 22333 once to join

UNC Lineberger Cancer Network

**Breast cancer can occur in women and rarely in men.**

True

False

Powered by **Poll Everywhere**

Start the presentation to see live content. For screen share software, share the entire screen. Get help at [polllev.com/help](https://polllev.com/help)

9

---

---

---

---

---

---

---

---

**BREAST CANCER**



Caring for the Patient with Breast Cancer  
Amy DePue, MSN RN BSN OCN CBCN  
UNC Breast Oncology  
October 25, 2022

10

---

---

---

---

---

---

---

---

**Objectives**

- Describe the types, stages, and diagnostic test available for treating the patient with breast cancer
- Discuss the treatment options, side effect management, emotional needs of the patient with breast cancer
- Discuss the importance of collaboration and teamwork to enhance the quality of care and patient outcomes

11

---

---

---

---

---


---

---

---

**Definition**

Breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast.



12

---

---

---


---

---

---

---

---



13

---

---

---


---

---

---

---

---



14

---

---

---

---

---

---

---

---

American Cancer Society

- <https://www.cancer.org/research/cancer-facts-statistics.html>

In this report, note the changes in individual cancer disease process.

- Table 1, page 6 Estimated # of new diagnoses/deaths as result**

<b>Men: 2710 new cases</b>	<b>Women: 287,850</b>
<b>Men: 530 deaths BC</b>	<b>Women: 43,250</b>

American Cancer Society, 2022

15

---

---

---

---

---


---

---

---

### Types of Breast Cancer

#### Ductal Carcinoma



**Ductal Carcinoma in situ (DCIS)**  
Abnormal cells are found only in the lining of the breast duct.

**Invasive Ductal Carcinoma**  
Cancer spreads outside the breast duct to surrounding normal tissue.

16

---

---

---

---

---


---

---

---

### Types of Breast Cancer

#### Lobular Carcinoma



**Lobular Carcinoma in situ (LCIS)**  
Abnormal cells are found only in the lobes of the breast.

**Invasive Lobular Carcinoma**  
Cancer spreads outside the lobes to surrounding normal tissue.

17

---

---

---

---

---

---


---

---

### Types of Breast Cancer

#### Inflammatory Breast Cancer

- Uncommon.
- Breast is warm, red, and swollen
- Skin of breast may also show a pitted appearance.



18

---

---

---

---

---

---

---

---

Symptoms and Signs of Breast Cancer

- Lump or change in the breast.
- Swelling (even if no distinct lump is felt)
- Skin irritation or dimpling
- Breast or nipple pain
- Nipple retraction (turning inward)
- Redness, scaliness, or thickening of the nipple or breast skin
- Nipple discharge (other than breast milk)

---

---

---

---

---

---

---

---

19

Risk Factor Models for predictive information

- Gail model
- [www.bcrisktool.cancer.gov/calculator.html](http://www.bcrisktool.cancer.gov/calculator.html)
- Age
- Race
- Gender
- Age at first menstrual cycle
- Biopsy
- Atypia
- First degree relative

National Cancer Institute

---

---

---

---

---

---

---

---

20

Gail model results

7.9%  
5-year breast cancer risk

Compared with 1.8% for the average 60 year old woman

34.3%  
Lifetime breast cancer risk

Compared with 9.1% for the average 60 year old woman

Next Steps

---

---

---

---

---

---

---

---

21

**RISK FACTORS**

<b>Modifiable</b>	<b>Non-modifiable</b>
Weight	Age
Exercise	Gender
Diet	Genetics
Hormonal use	Family History
Tobacco use	Previous radiation treatments
Alcohol consumption	

---

---

---

---

---

---

---

---

22

When poll is active, respond at [polllev.com/uncn](https://polllev.com/uncn)  
Text UNCLCN to 22333 once to join

**UNC** Lineberger Cancer Network

**Which of the following has been associated with an increased incidence of breast cancer in women?**

Powered by **UN Poll Everywhere**

---

---

---

---

---

---


---

---

23

**So, who needs mammograms and when?**

- American Cancer Society recommends:
- Average risk: annual screening mammogram starting age 45
- Average risk: biennial screening mammogram age 55-64
- Any woman, any age, with life expectancy of > 10 years
- Strong family history of breast cancer, begin at age 40
- Anyone with a male family member, begin age 40



---

---

---

---

---

---

---

---

24



**American Cancer Society** **New Breast Cancer Screening Guideline**  
for women with average risk

**AGE 40**  
Talk with your doctor about when to begin screening. **Women should have the opportunity to begin screening** if they choose.

**AGE 45**  
Begin **yearly mammograms** by age 45.

**AGE 55**  
Transition to mammograms **every other year** at age 55 or continue with annual mammography, depending on your preferences.

**AGE 55 +**  
**Continue to have regular mammograms** for as long as you're in good health.

25

---

---

---

---

---

---

---

---

**Screening Options**  
Mammogram

Mammogram, an x-ray of the breast, is the most common screening test for breast cancer.

26

---

---

---

---

---

---

---

---

**BI-RADS**

- Bi-rads indicates a finding on mammogram imaging
- Breast Imaging Reporting and Database System score
- Ranges from 0 to 6:
  - 0 = incomplete exam
  - 1 = normal results, breast density
  - 2 = Normal result, probably cyst
  - 3 = Probably normal but small risk of cancer, 6 month follow up
  - 4 = Suspicious finding, biopsy needed
  - 5 = Highly suspicious, biopsy needed with clinical correlation
  - 6 = Have breast cancer diagnosis, imaging done for treatment effect

27

---

---

---

---

---

---

---


---

**Screening Options**  
Magnetic Resonance Imaging (MRI)

Procedure that uses magnets, radio waves, and computers to make a series of pictures of areas inside the body.

Used with women who have one or more of the following:

- Gene changes (BRCA1 or BRCA2)
- Family history of breast cancer
- Genetic Syndromes (Li-Fraumeni, Cowden Syndrome)



28

---

---

---

---


---

---

---

---

**Screening Option: Clinical Breast Exam**



Checking for masses to confirm imaging or given prior to imaging. Goal is early detection of malignancy. Performed by doctor or NP/PA

29

---

---

---

---

---

---

---

---

**GENETICS**

- Genetic mutations indicate increased risk for breast cancer BRCA1 and BRCA2
- Family history important
- First degree relatives
- Male in the family with breast cancer diagnosis
- Ashkenazi Jewish heritage

30

---

---

---

---

---

---

---

---

When poll is active, respond at [polllev.com/uncncln](https://polllev.com/uncncln)  
Text UNCLCN to 22333 once to join

UNC  
UNC Lineberger Cancer Network

Which of the following statements regarding genetic predisposition to cancer is NOT correct?

- The BRCA1/BRCA2 gene mutations are associated with increased susceptibility to breast cancer and ovarian cancer.
- The BRCA1/BRCA2 gene mutations are more common among women with an eastern European background.
- The BRCA1/BRCA2 gene mutations are involved in approximately 30% of breast cancer patients.
- Breast cancer susceptibility genes are present in less than 1% of the general population.

Powered by Poll Everywhere

---

---

---

---

---

---




---

---

31

### Biopsy

- Core needle
- Stereotactic



---

---

---

---

---

---


---

---

32

### BIOPSY

- Surgical (open)



---

---

---

---

---

---


---

---

33

**BIOPSY**

- MRI guided
- Tomosynthesis guided



34

---

---

---


---

---

---

---

Axillary Node



35

---

---

---

---

---

---

---

**PATHOLOGY**

- INFORMATION THAT HELPS GUIDE TREATMENT
- GIVES PHENOTYPE  
ER +/PR+/HER2neu OR Triple negative
- SIZE  
Yes, size does matter
- GRADE  
1, 2, 3 = higher the grade the more proliferative the tumor
- Information about axillary lymph node status

36

---

---

---

---

---

---

---

### STAGING

- Staging often confused with pathological staging
- Pathological staging in the T(umor), N(ode), M(etastatic)
- Disease state staging is gathered to determine cancer growth other than the breast itself

---

---

---

---

---

---

---

---

37

### PATHOLOGICAL STAGING

- New staging levels since 2017
- Based on the T N M system
- Based on size, number of lymph nodes positive, and presence of metastatic disease
- Tumor size at or less **2cm is stage I**
- Tumor size at or less than **5 cm is stage II**
- Tumor size and greater than **5 cm is stage III**
- *Tumor of any size that is found outside of the breast tissue and is a cellular similarity to breast tissue is STAGE IV*

---

---

---

---

---


---

---

---

38

### SIZE DOES MATTER




---

---

---

---

---

---

---

---

39

**PHENOTYPE**

- Identifies treatments
- Hormone positive = Estrogen (ER)  
Progesterone (PR)
- HER2 Neu positive
- Other markers that are becoming more useful in treatment and clinical trials: Ki67, Ar (androgen receptor), HER3, etc
- Triple negative meaning no receptor's are positive and so limits the types of treatments for these patients. Triple negative are often more aggressive tumors.

---

---

---

---

---

---

---

---

40

**Disease State Staging**

- Positive lymph nodes
- Symptoms of pain, inflammation, body function decrease
- For initial staging, when appropriate:
  - CT chest/abdomen/pelvis *with contrast*
  - Bone Scan
- For subsequent staging, metastatic disease or local recurrence
  - Repeat CT and /or bone scan as indicated
- For CNS and brain staging
  - MRI *with and without contrast*

---

---

---

---

---

---

---

---

41

When poll is active, respond at [polllev.com/uncncln](https://polllev.com/uncncln)  
 Text **UNCLCN** to **22333** once to join

UNC Lineberger Cancer Network

**The MOST important objective of solid tumor staging is:**

- To provide information regarding risk factors
- To identify individuals a high risk for disease recurrence
- To determine performance status and eligibility for research protocols
- To provide the necessary information for individual treatment planning.

Powered by **Poll Everywhere**

Start the presentation to see live content. For screen share software, share the entire screen. Get help at [polllev.com/help](https://polllev.com/help)

---

---

---

---

---

---

---

---

42

### TREATMENT MODALITIES

- **MEDICAL ONCOLOGY**  
chemotherapy neo-adjuvant or adjuvant, curative or palliative
- **SURGICAL ONCOLOGY**  
mastectomy, lumpectomy, ax node dissection, palliative
- **RADIATION ONCOLOGY**  
post surgical and systemic therapy, palliative for symptom management

---

---

---

---

---

---

---

---

43

### MEDICAL ONCOLOGY

- Responsible for systemic therapy such as chemotherapy
- Responsible for medical management of side effects from chemotherapy
- Responsible for follow up care, including aromatase inhibitors or Tamoxifen for risk reduction
- Will follow the patient for 5 years minimum
- Will care for metastatic patients

---

---

---

---

---

---

---

---

44

### Predictive testing for Hormone positive breast cancer patients

- **Oncotype Dx**  
Genomic testing concerning benefit of chemotherapy and recurrence
- **Prosigna/Pam 50**  
Genomic testing for post menopausal women on AI/Tamoxifen
- **MammaPrint**  
Genomic testing for continued use of AI/Tamoxifen
- **Breast Cancer Index**  
Benefit for continued use of AI/Tamoxifen
- **Foundation Medicine**  
Genomic testing for other actionable mutations

---

---

---

---


---

---

---

---

45



46

---

---

---

---

---

---

---

---

**CHEMOTHERAPY**

- Systemic therapy
- Neo adjuvant, before surgery
- Adjuvant, post surgical
- Depends on phenotype
- Significant side effect management
- Understanding of oncological emergencies key to adherence

47

---

---

---

---

---

---

---

---

**CHEMOTHERAPY**

- Cytotoxic drug: lab checks for myelosuppression
- Side effects, think rapidly reproducing cells: GI, Hair follicles
- Alopecia: Cryotherapy ?
- Nausea/vomiting
- Neuropathy
- Constipation
- Cardiotoxicity in some drugs: follow with echocardiogram
- Most fatal side effect: Myelosuppression

48

---

---

---

---

---

---

---

---



Specific Chemo for Specific Phenotype

- Anthracyclines for triple negative:  
Doxorubicin
- Taxanes for Hormone receptor positive and triple negative:  
Paclitaxel, Docetaxel
- Targeted agents for HER2 positive :  
Trastuzumab, Pertuzumab

COMBINATION REGIMIN DEPENDS ON PHENOTYPE AND NODE STATUS

---

---

---

---

---

---

---

49

SUPPORTIVE DRUGS

- Ondansetron for nausea
- Prochlorperazine for nausea, but is sedating
- Olanzapine but only at night
- Neulasta for myelosuppression
- Dexamethasone for anthracycline
- Lorazepam for extreme nausea but also for sleep if taking dexamethasone

---

---

---

---

---

---

---

50

BIOSIMILARS

- NOT chemotherapy
- Utilizes body systems to fight the cancer
- Can alter specific cascades to reduce hormones
- Receptors important for cancer growth
- More research needed
- Neulasta biosimilar is on the market, lower cost: UDENYCA
- PARPi for BRCA carriers: Olaparib for one...

---

---

---

---

---

---

---

51

**TARGETED THERAPY**

- Monoclonal antibodies for HER2 positive breast cancer
- Cardiotoxic drugs

Trastuzumab  
Pertuzumab

Chemo combination drug:  
Kadcyla: chemotherapy + monoclonal antibody

---

---

---

---

---

---

---

52

**Metastatic Disease**

- Many drugs for disease control and symptomology
- Oral and IV
- Ibrance
- Xeloda
- Use of radiation therapy for palliative treatment for pain

---

---

---

---

---

---

---

53

**METASTATIC BREAST CANCER**

- Bone, Liver, Lung, Brain
- About 6% of metastatic patients present with metastatic disease
- Imaging useful for diagnosis, CT C/A/P, MRI, US
- Biopsy proven for treatment
- Symptoms most often show as pain, nausea, vision changes
- Palliative care to be introduced early

Cancer.net

---

---

---

---

---

---

---

54

**Treatment Options**  
Hormone Therapy

- Cancer treatment that removes hormones or blocks their action and stops cancer cells from growing.
- Tamoxifen is often given to patients with early localized breast cancer that can be removed by surgery and those with metastatic breast cancer




Image Source: The Drug Store

---

---

---

---

---

---

---

---

55

**Treatment side effects: systemic therapy**

- Comorbidity plays a part
- Must check renal function, liver function, baseline labs
- Heart failure
- Blood clots
- Early menopausal symptoms
- Secondary malignancy possible, such as leukemia
- Know oncological emergency

---

---

---

---

---

---

---

---

56

**SURGICAL ONCOLOGY**

Often leads the way for treatment

If adjuvant, reason is often due to size of tumor

Consists of lumpectomy  
mastectomy  
node dissection  
Sentinel node

---

---

---

---

---


---

---

---

57

Lumpectomy



58

---

---

---

---


---

---

---

---

MASTECTOMY: Skin sparing



59

---

---

---

---


---

---

---

---

MASTECTOMY: Radical



60

---

---

---


---

---

---

---

---



61

---

---


---

---

---

---

---



62

---

---


---

---

---

---

---



63

---

---

---

---

---

---

---

RADIATION ONCOLOGY

- Required if positive surgical margins
- Positive lymph nodes
- Treatment for 4 to 6 weeks
- Side effects: redness, induration, peeling
  
- Palliative care for bone or brain mets
- Whole brain
- SRS

---

---

---

---

---

---

---

---

64

Treatment side effects: radiation therapy

- Inflammation of the lung
  
- Upper extremity lymphedema
  
- Trunk lymphedema
  
- Higher risk of developing breast cancer in the contralateral breast

---

---

---

---

---

---

---

---

65

TEST QUESTION:

A 67 Y/O woman had a diagnostic mammogram and ultrasound that revealed a 30 x 25 x 21 mm lobulated irregular hypoechoic finding in the left breast. A core biopsy revealed a high-grade, triple negative infiltrating mammary carcinoma. MRI reveals an extension of the original tumor from the chest wall to the anterior skin and there is questionable chest wall involvement by tumor.

AT THIS TIME, the MOST appropriate treatment choice is...

---

---

---

---

---

---

---

---

66

When poll is active, respond at [polllev.com/uncn](https://polllev.com/uncn)  
 Text UNCLCN to 22333 once to join

UNC Lineberger Cancer Network

**AT THIS TIME, the MOST appropriate treatment choice is...**

- Surgery followed by anthracycline/taxane-containing chemotherapy followed by radiation
- Neoadjuvant taxane therapy followed by surgery, then followed by radiation
- Neoadjuvant anthracycline/taxane-containing chemotherapy followed by surgery, then followed by radiation treatment
- Surgery followed by taxane therapy and radiation therapy

Powered by Poll Everywhere

Start the presentation to see live content. For screen share software, share the entire screen. Get help at [polllev.com/help](https://polllev.com/help)

67

---

---

---

---

---

---

---

---

UNC Lineberger Cancer Network

**From the question above, would this patient be a candidate for adding an aromatase inhibitor following radiation? Why or why not?**

Powered by Poll Everywhere

Start the presentation to see live content. For screen share software, share the entire screen. Get help at [polllev.com/help](https://polllev.com/help)

68

---

---

---

---

---


---

---

---

**SURVIVORSHIP**

- Patient is survivor from moment of diagnosis
- Survivorship happens when active treatment is complete
- Will be followed by oncology through 5 years, often 10
- Return to primary care physician



69

---

---

---

---

---

---

---

---

Emotional Needs of the patient with breast cancer:

- Psycho – social needs vary
- Resources may be limited
- Often have to depend on family and friends
- MUST talk about real racial disparities
- TRUST significant factor for better outcomes
- Build a team




---

---

---

---

---

---

---

---

70

NURSING CARE for Patients with Breast Cancer

- Body
- Mind
- Spirit
- Extends to caregivers
- Includes social issues
- Often complex but never wrong

---

---

---

---

---

---

---

---

71

Thought:

“As a nurse, we have the opportunity to heal the heart, mind, soul and body of our patients, their families and ourselves. They may forget your name, but they will never forget how you made them feel!”

Maya Angelou  
 Author, poet, and civil rights activist




---

---

---

---

---

---

---

---

72



References

- American Cancer Society  
[www.cancer.org](http://www.cancer.org)
- American Society of Clinical Oncology  
[www.cancer.net](http://www.cancer.net)
- Yarbro, C.H., Wujcik, D., & Gobel, B. H., (2013) *Breast Care Certification Review*. Burlington MA: Jones and Bartlett Learning

73

---

---

---

---

---

---

---

---

UNC Lineberger Comprehensive Cancer Center  
UNC Lineberger Cancer Network

**Questions/Comments?**

Powered by **GoPoll Everywhere**  
Start the presentation to see live content. For screen share software, share the entire screen. Get help at [poller.com/help](http://poller.com/help)

74

---

---

---

---

---

---

---

---

**THANK YOU!**

University Cancer Research Fund

UNC LINEBERGER COMPREHENSIVE CANCER CENTER

UNC Lineberger Cancer Network

The Telehealth Team

Tim Poe, Director

Veneranda Obare, Technology Support Specialist     Andrew Dodgson, OPR, Continuing Education Specialist  
 Jon Powell, PhD, Coaching & Executive Specialist     Nadja Brown, Health Administration Support Specialist  
 Oliver Marth, Technology Support Specialist     Patrick Muscarella, Technology Support Specialist

75

---

---

---

---

---

---

---

---

**UPCOMING LIVE WEBINARS**

UNC Lineberger Cancer Network  
**NORTH CAROLINA COMMUNITY COLLEGE**  
ONCOLOGY WEBINARS

**February 21**  
**12:00 PM**      **Caring for Patients with Head and Neck Cancers**  
 Trevor Rackman, MD, FACS  
 Catherine J. Lumley, MD

**March 21**  
**12:00 PM**      **Caring for Patients with GI Cancers**  
 Melanie N. Allard, DNP, APRN, FNP-BC, CCRN

For a complete listing and details on coming events visit:  
[learn.uncicn.org/cco](http://learn.uncicn.org/cco)

76

---

---

---

---

---

---

---

---

**SELF-PACED, ONLINE COURSES**

UNC Lineberger Cancer Network  
**NORTH CAROLINA COMMUNITY COLLEGE**  
ONCOLOGY WEBINARS

**Gynecologic Cancers: A Team Approach to Women's Health Care**  
 Daniel Clarke-Pearson, MD  
 Lyn Filip, RN, BSN, OCN

**Palliative Care and Hospice for the Cancer Patient**  
 Gary Winzelberg, MD, MPH  
 Jenny Hanspal, RN, BSN, MS, OCN

Today's webinar will be available in November 2022 as a **FREE**, Self-Paced, Online Course

For a complete listing and details on coming events visit:  
[learn.uncicn.org/cco](http://learn.uncicn.org/cco)

77

---

---

---

---


---

---

---

---

**EVALUATION SURVEY**



Your feedback is greatly appreciated!

**Please visit:**  
[uncicn.org/eval](http://uncicn.org/eval)

78

---

---

---

---

---

---

---

---

**THANK YOU FOR PARTICIPATING!**

**UNC Lineberger Cancer Network**

Email: [unclcn@unc.edu](mailto:unclcn@unc.edu)  
Call: **919-445-1000**

*Send us an email to sign up for our monthly e-newsletter.*  
Check us out at [unclcn.org](http://unclcn.org)

 [facebook.com/unclcn](https://facebook.com/unclcn)  [@unc\\_cn](https://twitter.com/unc_cn)

---

---

---

---

---

---

---

79